The efficacy of calcitriol and vitamin D3 supplementation on calcium metabolism and bone turnover markers in Shanghai postmenopausal women

Bone ◽  
2010 ◽  
Vol 47 ◽  
pp. S427 ◽  
Author(s):  
Hao Zhang ◽  
Qi-ren Huang ◽  
Zhen-lin Zhang
Keyword(s):  
Bone Turnover ◽  
Postmenopausal Women ◽  
Vitamin D3 ◽  
Bone Turnover Markers ◽  
Calcium Metabolism ◽  
Vitamin D3 Supplementation ◽  
Turnover Markers

Twelve-weeks Oral Spray Vitamin D3 Supplementation Does Not Alter Bone Turnover Markers In Collegiate Gaelic Footballers

2017 ◽  
Vol 49 (5S) ◽  
pp. 105
Author(s):  
Sharon M. Madigan ◽  
Joshua Todd ◽  
Emeir McSorley ◽  
L. Kirsty Pourshahidi ◽  
Eamon Laird ◽  
...  
Keyword(s):  
Bone Turnover ◽  
Vitamin D3 ◽  
Bone Turnover Markers ◽  
Vitamin D3 Supplementation ◽  
Turnover Markers

scholarly journals Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis

2016 ◽  
Vol 2016 ◽  
pp. 1-6 ◽  
Author(s):  
A. Sánchez ◽  
L. R. Brun ◽  
H. Salerni ◽  
P. R. Costanzo ◽  
D. González ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Bone Turnover ◽  
Postmenopausal Women ◽  
Bone Mineral ◽  
Bone Turnover Markers ◽  
Control Group ◽  
Bone Resorption Marker ◽  
Similar Response ◽  
Mineral Density ◽  
Turnover Markers

The aim of this study was to evaluate the effect of denosumab (Dmab) on bone mineral density (BMD) and bone turnover markers after 1 year of treatment. Additionally, the effect of Dmab in bisphosphonate-naïve patients (BP-naïve) compared to patients previously treated with bisphosphonates (BP-prior) was analyzed. This retrospective study included 425 postmenopausal women treated with Dmab for 1 year in clinical practice conditions in specialized centers from Argentina. Participants were also divided according to previous bisphosphonate treatment into BP-naïve and BP-prior. A control group of patients treated with BP not switched to Dmab matched by sex, age, and body mass index was used. Data are expressed as mean ± SEM. After 1 year of treatment with Dmab the bone formation markers total alkaline phosphatase and osteocalcin were significantly decreased (23.36% and 43.97%, resp.), as was the bone resorption marker s-CTX (69.61%). Significant increases in BMD were observed at the lumbar spine, femoral neck, and total hip without differences between BP-naïve and BP-prior. A better BMD response was found in BP-prior group compared with BP treated patients not switched to Dmab.Conclusion. Dmab treatment increased BMD and decreased bone turnover markers in the whole group, with similar response in BP-naïve and BP-prior patients. A better BMD response in BP-prior patients versus BP treated patients not switched to Dmab was observed.

Sign in / Sign up

Export Citation Format

Share Document